SCHEMBL21592286

SCHEMBL21592286

COc1cccc(-c2cc3occ(CN(CCCn4ccnc4)Cc4ccncc4)c(=O)c3cc2F)c1

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP11B1 P15538 7/20 0.46
CYP11B2 P19099 7/20 0.46
LMNA P02545 1/20 0.39
RAB9A P51151 1/20 0.39
ACHE P22303 1/20 0.39
KDM4E B2RXH2 1/20 0.38
ALDH1A1 P00352 1/20 0.38
TOP1 P11387 1/20 0.38
QPCT Q16769 3/20 0.38
GSK3B P49841 2/20 0.37
CYP19A1 P11511 3/20 0.36
MAPT P10636 2/20 0.36
PPARG P37231 1/20 0.36
PPARD Q03181 1/20 0.36
PPARA Q07869 1/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21592280 0.92 CYP11B1 (0.48) CYP11B1CYP11B2KDM4EALDH1A1QPCT
SCHEMBL21592273 0.90 CYP11B1 (0.53) CYP11B1CYP11B2LMNARAB9ATOP1
SCHEMBL21591430 0.86 CYP11B1 (0.64) CYP11B1CYP11B2ALDH1A1CYP19A1KMT2A
SCHEMBL21591446 0.83 CYP11B1 (0.55) CYP11B1CYP11B2KDM4EALDH1A1QPCT
SCHEMBL21591436 0.82 CYP11B1 (0.45) CYP11B1CYP11B2RAB9ACYP19A1MEN1
SCHEMBL21592247 0.82 CYP11B1 (0.46) CYP11B1CYP11B2ACHEKDM4EALDH1A1
SCHEMBL21591433 0.80 CYP11B1 (0.52) CYP11B1CYP11B2RAB9AKDM4EALDH1A1
SCHEMBL21591489 0.80 CYP11B1 (0.62) CYP11B1CYP11B2RAB9AKDM4ECYP19A1
SCHEMBL21591568 0.79 CYP11B1 (0.53) CYP11B1CYP11B2RAB9AQPCTGSK3B
SCHEMBL21591502 0.78 CYP11B1 (0.59) CYP11B1CYP11B2RAB9ACYP19A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12162863-B2 Modulators of stimulator of interferon genes (STING) Ryvu Therapeutics S.A. (PL) 2024-12-10 US disclosed
US-20220402898-A1 MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) Ryvu Therapeutics S.A. (PL) 2022-12-22 US disclosed
US-20220402898-A1 MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) Ryvu Therapeutics S.A. (PL) 2022-12-22 US disclosed
WO-2019238786-A1 MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) Ryvu Therapeutics S.A. (PL) 2019-12-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12162863-B2 Modulators of stimulator of interferon genes (STING) STING1, IRF3, CGAS CYP11B1 43/4885CYP11B2 50/4885LMNA 3267/4885
US-20220402898-A1 MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) STING1, IRF3, CGAS CYP11B1 43/4885CYP11B2 50/4885LMNA 3267/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.